KEYNOTE-590: Phase III study of first-line chemotherapy with or without pembrolizumab for advanced esophageal cancer

Treatment options for patients with advanced esophageal or esophagogastric junction (EGJ) cancer are limited. Current guidelines for first-line treatment of advanced esophageal or EGJ cancer recommend chemotherapy containing a platinum and a fluoropyrimidine agent. Pembrolizumab demonstrated antitum...

Full description

Saved in:
Bibliographic Details
Published in:Future oncology (London, England) England), 2019-04, Vol.15 (10), p.1057-1066
Main Authors: Kato, Ken, Shah, Manish A, Enzinger, Peter, Bennouna, Jaafar, Shen, Lin, Adenis, Antoine, Sun, Jong-Mu, Cho, Byoung Chul, Özgüro lu, Mustafa, Kojima, Takashi, Kostorov, Vladimir, Hierro, Cinta, Zhu, Ying, McLean, Lee Anne, Shah, Sukrut, Doi, Toshihiko
Format: Article
Language:English
Subjects:
Adolescent
Adult
Aged
Aged, 80 and over
Antibodies, Monoclonal, Humanized - administration & dosage
Antineoplastic Combined Chemotherapy Protocols - therapeutic use
Cancer therapies
Carcinoma, Squamous Cell - drug therapy
Carcinoma, Squamous Cell - secondary
Chemotherapy
Double-Blind Method
Esophageal cancer
Esophageal Neoplasms - drug therapy
Esophageal Neoplasms - pathology
esophagogastric junction cancer
Female
Fluorouracil - administration & dosage
Follow-Up Studies
gastrointestinal/esophageal
Gene expression
Health risk assessment
Humans
Immunotherapy
Male
Metastasis
Middle Aged
Monoclonal antibodies
PD-1
PD-L1
pembrolizumab
Prognosis
Research Design
Response rates
Squamous cell carcinoma
squamous cell carcinoma of the esophagus
Studies
Survival Rate
Targeted cancer therapy
Tumors
Young Adult
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Treatment options for patients with advanced esophageal or esophagogastric junction (EGJ) cancer are limited. Current guidelines for first-line treatment of advanced esophageal or EGJ cancer recommend chemotherapy containing a platinum and a fluoropyrimidine agent. Pembrolizumab demonstrated antitumor activity in previously treated patients with advanced esophageal cancer and in patients with gastroesophageal junction cancer. To describe the design and rationale for the randomized, double-blind, placebo-controlled Phase III KEYNOTE-590 study, which will be conducted to investigate pembrolizumab in combination with chemotherapy as first-line treatment in patients with advanced esophageal or EGJ cancer. : NCT03189719.
ISSN:1479-6694
1744-8301
DOI:10.2217/fon-2018-0609